Faculty Collaboration Database

All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. J Clin Oncol 1993 Aug;11(8):1489-95

Date

08/01/1993

Pubmed ID

8336187

DOI

10.1200/JCO.1993.11.8.1489

Scopus ID

2-s2.0-0027227770 (requires institutional sign-in at Scopus site)   58 Citations

Abstract

PURPOSE: We conducted a study to evaluate the tolerance to and biologic effects of all-trans retinoic acid in patients with myelodysplastic syndrome.

PATIENTS AND METHODS: Thirty-nine patients with myelodysplastic syndrome were treated with oral all-trans retinoic acid for 6 weeks. Dose levels were 10, 25, 50, 100, 150, 200, and 250 mg/m2/d. At least three patients were treated on each dose level.

RESULTS: The most common side effects were mucocutaneous dryness and erythema, and hypertriglyceridemia. Dose-limiting side effects were diverse and included dermatitic problems, sensorineural hearing loss, headaches, nausea and vomiting, myalgias, and dyspnea. The maximum-tolerated dose was 150 mg/m2/d. Only one response was seen among 29 patients considered assessable for response.

CONCLUSION: All-trans retinoic acid can be safely administered to patients at doses up to 150 mg/m2/d for 6 weeks. However, as administered in this study, this compound does not appear to have significant activity in myelodysplastic syndromes.

Author List

Kurzrock R, Estey E, Talpaz M

Author

Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Administration, Oral
Adult
Aged
Female
Humans
Male
Middle Aged
Myelodysplastic Syndromes
Treatment Outcome
Tretinoin